Abstract:Khaled S Allemailem, 1 Ahmad Almatroudi, 1 Arshad Husain Rahmani, 1 Faris Alrumaihi, 1 Arwa Essa Alradhi, 2 Amal M Alsubaiyel, 3 Mohammad Algahtani, 4 Rand Mohammad Almousa, 5 Ali Mahzari, 6 Abdulmajeed AA Sindi, 7 Gasim Dobie, 8 Amjad Ali Khan 9 1 Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia; 2 General Administration for Infectious Disease Control, Ministry of Health, Riyadh 12382, Saudi Arabia; 3 Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia; 4 Department of Laboratory & Blood Bank, Security Forces Hospital, Mecca 21955, Saudi Arabia; 5 Department of Education, General Directorate of Education, Qassim 52361, Saudi Arabia; 6 Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha 65527, Saudi Arabia; 7 Department of Basic Medical Sciences, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha 65527, Saudi Arabia; 8 Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Jazan University, Gizan 82911, Saudi Arabia; 9 Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia Correspondence: Amjad Ali Khan, Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah, 51452, Saudi Arabia, Email The genome editing approach by clustered regularly interspaced short palindromic repeats (CRISPR)/associated protein 9 (CRISPR/Cas9) is a revolutionary advancement in genetic engineering. Owing to its simple design and powerful genome-editing capability, it offers a promising strategy for the treatment of different infectious, metabolic, and genetic diseases. The crystal structure of Streptococcus pyogenes Cas9 (SpCas9) in complex with sgRNA and its target DNA at 2.5 Å resolution reveals a groove accommodating sgRNA:DNA heteroduplex within a bilobate architecture with target recognition (REC) and nuclease (NUC) domains. The presence of a PAM is significantly required for target recognition, R-loop formation, and strand scission. Recently, the spatiotemporal control of CRISPR/Cas9 genome editing has been considerably improved by genetic, chemical, and physical regulatory strategies. The use of genetic modifiers anti-CRISPR proteins, cell-specific promoters, and histone acetyl transferases has uplifted the application of CRISPR/Cas9 as a future-generation genome editing tool. In addition, interventions by chemical control, small-molecule activators, oligonucleotide conjugates and bioresponsive delivery carriers have improved its application in other areas of biological fields. Furthermore, the intermediation of physical control by using heat-, light-, magnetism-, and ultrasound-responsive elements attached to this molecular tool has revolutionized genome editing further. These strategies significantly reduce CRISPR/Cas9's undesirable off-target effects. However, other undesirable effects still offer some challenges for comprehensive clinical translation using this genome-editing approach. In this review, we summarize recent advances in CRISPR/Cas9 structure, mechanistic action, and the role of small-molecule activators, inhibitors, promoters, and physical approaches. Finally, off-target measurement approaches, challenges, future prospects, and clinical applications are discussed. Keywords: CRISPR/Cas9, sgRNA, genome editing, off-target effects, spatiotemporal control, clinical translation Clustered regularly interspaced short palindromic repeats (CRISPR)/associated protein 9 (CRISPR/Cas9) are a class of microbial defense mechanisms against mobile genetic elements, plasmids, and phage infections. 1,2 This endonuclease system has been proposed as an innovative tool for genome editing, genome imaging, epigenetic modulation, and transcriptional perturbation. The genome editing technology by using CRISPR/Cas9 is used to precisely manipulate functional genes involved in disease progression, correct disease-initiating mutations, activate tumor suppressor genes, and inactivate activated oncogenes. 3–5 CRISPR/Cas9 technology can be used to treat a variety of infectious and genetic diseases such as metabolic disorders, cardiovascular diseases, Alzheimer's disease, and human immunodeficiency virus (HIV) infections, 6,7 because of its simple design and ability to simultaneously edit multiple sites. 8 Other DNA editing approaches such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) are also used for -Abstract Truncated-

A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in <i>Streptomyces</i>

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

Computationally guided high-throughput engineering of an anti-CRISPR protein for precise genome editing in human cells

High-fidelity SpCas9-HF1 enhances accuracy of cell cycle-dependent genome editing by increasing HDR efficiency, and by reducing off-target effects and on-target mutation rates.

Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing

Programmable downsizing of CRISPR-Cas9 activity for precise and safe genome editing

Disabling Cas9 by an anti-CRISPR DNA mimic

Improved genome editing by an engineered CRISPR-Cas12a

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in Streptomyces

Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers.

Discovery of potent and versatile CRISPR-Cas9 inhibitors engineered for chemically controllable genome editing

A comprehensive appraisal of mechanism of anti-CRISPR proteins: an advanced genome editor to amend the CRISPR gene editing

Cell-specific CRISPR/Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins

Cell-specific CRISPR–Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins

Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications

Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering

A Broad-Spectrum Inhibitor of CRISPR-Cas9

Recent Updates of the CRISPR/Cas9 Genome Editing System: Novel Approaches to Regulate Its Spatiotemporal Control by Genetic and Physicochemical Strategies